FDA gave approval to Oligomannate 甘露寡糖二酸 (otherwise referred to as GV-971), developed by Chinese company Shanghai Green Valley Pharmaceuticals 上海绿谷制药 to progress to international multi-center clinical trials involving 2,000 mild and moderate Alzheimer’s cases.
9-25-20 Phase II trial – GV-971 was safe and well tolerated. GV-971 900 mg was chosen for phase III clinical study.
![](http://roughlife.com/b/wp-content/uploads/2020/08/single-line-border-clipart-6-1024x76.jpg)